To discuss the antimicrobial activity, pharmacokinetics, clinical efficacy, and adverse effect profile of piperacillin/tazobactam, a new beta-lactam/beta-lactamase inhibitor combination.
Data Sources:
Literature was identified by MEDLINE search of the medical literature, review of selected references, and data provided by the manufacturer.
Study Selection:
In vitro susceptibility data were surveyed from studies following the methods of the National Committee for Clinical Laboratory Standards. Data evaluating clinical efficacy were selected from all published trials and abstracts. Additional information concerning safety, chemistry, and pharmacokinetics was reviewed.
Data Synthesis:
The antimicrobial activity of piperacillin is enhanced by addition of tazobactam against gram-positive, gram-negative, and anaerobic bacteria. Tazobactam is active against a broad spectrum of plasmid and chromosomally mediated enzymes and has minimal ability to induce class I chromosomally mediated beta-lactamase enzymes. Piperacillin/tazobactam's expanded activity appears encouraging in the treatment of mixed aerobic and anaerobic infections. Direct comparisons of ticarcillin/clavulanate and piperacillin/tazobactam for the treatment of lower respiratory tract infections showed piperacillin/tazobactam to be clinically superior, and in the treatment of skin and soft tissue infections the 2 agents were comparable. For the treatment of intraabdominal infections, piperacillin/tazobactam was at least as effective as imipenem/cilastatin and clindamycin plus gentamicin.
Conclusions:
The combination of tazobactam with piperacillin results in an antimicrobial agent with enhanced activity against most beta-lactamase–producing organisms. Preliminary data indicate that piperacillin/tazobactam has proven clinical efficacy in the treatment of a variety of infections, especially polymicrobic infections.
Get full access to this article
View all access options for this article.
References
1.
HigashitaniF, HyodoA, IshidaN, InoueM, MitsushashiS.Inhibition o. β-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin. J Antimicrob Chemother1990;25:567-74.
2.
Package information. Zosyn (piperacillin/tazobactam). Pearl River, NY: Lederle Laboratories, October, 1993.
3.
SörgelF, KinzigM.The chemistry, pharmacokinetics, and tissue distribution of piperacillin/tazobactam. J Antimicrob Chemother1993;31(suppl A):S39-60.
4.
GutmannL, KitzisMD, YamabeS, AcarJF. Comparative evaluation of a new β-lactamase inhibitor with different β-lactam antibiotics against bacteria harboring known β-lactamases. Antimicrob Agents Chemother1986;29:955-7.
5.
EliopoulosGM, KlimmK, FerraroyMJ, JacobyGA, MoelleringRC. Comparative in vitro activity of piperacillin combined with beta-lactamase inhibitor tazobactam (YTR 830). Diagn Microbiol Infect Dis1989;12:481-8.
6.
KuckNA, JacobusNV, PetersenPJ, WeissWJ, TestaRT. Comparative in vitro and in vivo activities of piperacillin combined with the β-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam. Antimicrob Agents Chemother1989;33:1964-9.
7.
ThomsonKS, WeberDA, SandersCC, SandersWE. β-lactamase production in members of the family Enterobacteriaceae and resistance to β-lactam-enzyme inhibitor combinations. Antimicrob Agents Chemother1990;34:622-7.
8.
StobberinghEE. In vitro effect of YTR 830 (tazobactam) in plasmid and chromosomally mediated β-lactamases. Chemotherapy1990;36:209-14.
9.
WhiteRL, BurgessD, BossoJ, WalkerM.Comparison of susceptibility testing methods of beta-lactam/beta-lactamase inhibitor combinations based on human pharmacokinetics (abstract 74). Pharmacotherapy1993:13:279.
10.
JonesRN, BarryAL. Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830). Diagn Microbiol Infect Dis1989;12:495-510.
11.
PfallerMA, BarryAL, FuchsPC, GerlachEH, HardyDJ, McLaughlinJC. Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/tazobactam. Eur J Clin Microbiol Infect Dis1992;11:728-32.
FassRJ, PriorRB. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate. Antimicrob Agents Chemother1989;33:1268-74.
14.
MehtarS, DrabuYJ, BlakemorePH. The in-vitro activity of piperacillin/tazobactam, ciprofloxacin, ceftazidime and imipenem against multiple resistant gram-negative bacteria. J Antimicrob Chemother1990;25:915-9.
15.
RohrM, BöckmannU, EndrigkeitS, SchützK, NierH.Antibiotic therapy and perioperative prophylaxis in acute appendicitis with tazobactam/piperacillin (abstract 1435). Proceedings of the 18th International Congress of Chemotherapy, Stockholm, June 27–July 2, 1993:362.
16.
KnappCC, Sierra-MaderoJ, WashingtonJA. Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830; CL-298,741) against clinical isolates and against mutants derepressed for class I beta-lactamase. Diagn Microbiol Infect Dis1989;12:511-5.
17.
VeneziaRA, YocumDM, RobbianoEM, EcholsRM. Comparative in vitro activities of a new quinolone WIN 57273, and piperacillin plus tazobactam against anaerobic bacteria. Antimicrob Agents Chemother1990;34:1858-61.
18.
JacobusNV, ImmermannFW, GupleJM, TestaRT. Susceptibility of anaerobes in phase III clinical studies of piperacillin/tazobactam. Clin Infect Dis1993;16(suppl 14):S344-8.
19.
WexlerHM, MolitorisE, FinegoldSM. Effect of β-lactamase inhibitors on the activities of various β-lactam agents against anaerobic bacteria. Antimicrob Agents Chemother1991;35:1219-24.
20.
WiseR, LoganM, CooperM, AndrewsJM. Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin. Antimicrob Agents Chemother1991;35:1081-4.
21.
KinzigM, SörgelF, BrismarB, NordCE. Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery. Antimicrob Agents Chemother1992;36:1997-2004.
22.
CheungWK, GreeneDS, KuyeO, ShinK, TonelliAP, HoustonA, Pharmacokinetics of YTR 830 and piperacillin after intravenous coadministration (abstract). Program and Abstracts of the 6th Mediterranean Congress of Chemotherapy1988, May22-27:159.
23.
RohrM, BöckmannU, EndrigkeitS, SchützK, NierH.Antibiotic therapy and perioperative prophylaxis in acute appendicitis with tazobactam/piperacillin (abstract 1435). Proceedings of the 18th International Congress of Chemotherapy, Stockholm, June 27–July 2, 1993:362.
24.
GoldfarbJ, ReedM, YamashitaT, LemonE, BlumerJ.Pharmacokinetic and dose escalation study of piperacillin/tazobactam in infants and children (abstract 1230). Proceedings of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, October 11–17, 1992:316.
25.
JohnsonCA, HalstensonCE, KellowayJS, ShapiroBE, ZimmermanSW, TonelliA, Single dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease. Clin Pharmacol Ther1992;51:32-41.
26.
ShlaesDM, BaughanR, BoylenCT, ChanJC, CharanNB, CormierYC, Piperacillin/tazobactam compared with bicarcillin/clavulanate in community acquired bacterial lower respiratory tract infections. J Antimicrob Chemother1994;34:565-7.
27.
BrismarB, MalmborgAS, TunevallG, WretlindB, BergmanL, MentzingL, Piperacillin–tazobactam versus imipenem–cilastatin for treatment of intra-abdominal infections. Antimicrob Agents Chemother1992;36:2766-73.
28.
NiinikoskiJ, HaviaT, AlhavaE, PääkkönenM, MiettinenP, KivilaaksoE.Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections. Surg Gynecol Obstet1993;176:255-61.
29.
KarranS.Clinical efficacy and cost effectiveness of piperacillin/tazobactam vs. ampicillin plus gentamicin plus metronidazole in the treatment of intraabdominal infections (abstract 5028). Proceedings of the 18th International Congress of Chemotherapy, Stockholm, June 27–July 2, 1993:403.
30.
PolkHC, FinkMP, LaverdiereM, WilsonSE, GarberGE, BariePS, Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infection. Am Surg1993;59:598-605.
31.
TanJS, WishnowRM, TalanDA, DuncansonFP, NordenCW, and the Piperacillin/Tazobactam Skin and Skin Structure Study Group. Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. Antimicrob Agents Chemother1993;37:1580-6.
32.
The International Antimicrobial Therapy Co-operative Group of the European Oncology Research Trials Cooperative. Piperacillin/tazobactam plus amikacin versus ceftazidime plus amikacin as empirical therapy for fever in patients with granulocytopenia: a prospective, randomized, multicenter study of efficacy, safety, and tolerance (abstract 645). Proceedings of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, October17-20, 1993:237.
33.
MarieJP, VekoffA, Cony-MakhoulP, FiereD, GuyH, HerbrechtR, A randomized trial of piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin in 222 febrile neutropenic patients (abstract 647). Proceedings of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, October17-20, 1993:237.
34.
MicozziA, NucciM, VendittiM, GentileG, GirmeniaC, MeloniG, Piperacillin/tazobactam/amikacin versus piperacillin/amikacin/teicoplanin in the empirical treatment of neutropenic patients. Eur J Clin Microbiol Infect Dis1993;12:1-8.
35.
MoutonY, LeroyO, BeuscartC, ChidiacC, SennevilleE, AjanaF, Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections. J Antimicrob Chemother1993;31(suppl A):S87-95.
36.
LoosU, Piperacillin/Tazobactam Study Group. Tazobactam/piperacillin in the treatment of respiratory tract infections (abstract 8). Proceedings of the 4th Biennial Conference on Chemotherapy of Infectious Diseases and Malignancies, Prague, August 30–September 1, 1992.
37.
BodmannKF. German multicenter study with tazobactam/piperacillin 2.5gm t.i.d. in patients with lower respiratory tract infections (abstract 12). Proceedings of the 4th Biennial Conference on Chemotherapy of Infectious Diseases and Malignancies, Prague, August 30–September 1, 1992.
38.
VogelF.The efficacy and safety of tazobactam/piperacillin in the treatment of lower respiratory tract infections (abstract 131). Proceedings of the 4th Biennial Conference on Chemotherapy of Infectious Diseases and Malignancies, Prague, August 30–September 1, 1992.
39.
VestweberKH, GründelE, EbertJ, KujathP.Intra-abdominal infections and the efficacy of piperacillin/tazobactam. Infect Med1993;10(suppl A):S33-42.
40.
LippertH.Perioperative prophylaxis and therapy with tazobactam/piperacillin in patients with acute and perforated appendicitis (abstract 132). Proceedings of the 4th Biennial Conference on Chemotherapy of Infectious Diseases and Malignancies, Prague, August 30–September 1, 1992.
41.
KujathP.Perioperative prophylaxis and pharmacokinetics of tazobactam/piperacillin in intraabdominal surgery (abstract 133). Proceedings of the 4th Biennial Conference on Chemotherapy of Infectious Diseases and Malignancies, Prague, August 30–September 1, 1992.
42.
TappA, WiseB, CardozoL.Efficacy and safety of piperacillin/tazobactam in gynaecological infections. Infect Med1993;10(suppl A):S61-4.
43.
MüllerT, TasslerH.Efficacy and safety of tazobactam/piperacillin in the treatment of bone and joint infections (abstract 15). Proceedings of the 4th Biennial Conference on Chemotherapy of Infectious Diseases and Malignancies, Prague, August 30–September 1, 1992.
44.
TasslerH, CullmannW, ElhardtD.Therapy of soft tissue infections with tazobactam/piperacillin. J Antimicrob Chemother1993;31(suppl A):S105-12.
45.
NaberKG. Acute pyelonephritis and complicated urinary tract infections: treatment with tazobactam/piperacillin (abstract 9). Proceedings of the 4th Biennial Conference on Chemotherapy of Infectious Diseases and Malignancies, Prague, August 30–September 1, 1992.
46.
SandersJW, PoweNR, MooreRD. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta-analysis. J Infect Dis1991;164:907-16.
47.
SweetRL, RoyS, FaroS, O'brienWF, SanfilippoJS, SeidlinM, Piperacillin and tazobactam versus clindamycin and gentamicin in the treatment of hospitalized women with pelvic infection. Obstet Gynecol1994;83:280-6.
48.
GentryLO, JemsekJG, NatelsonEA. Effect of sodium piperacillin on platelet function in normal volunteers. Antimicrob Agents Chemother1981;19:532-3.
